FDA asked during a public hearing on cannabis products whether patients taking unapproved cannabis products were monitored for adverse events. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
